Literature DB >> 8058634

Transcellular permeability of chlorpromazine demonstrating the roles of protein binding and membrane partitioning.

G A Sawada1, N F Ho, L R Williams, C L Barsuhn, T J Raub.   

Abstract

Transcellular permeability of the neuroleptic-anesthetic chlorpromazine (CPZ) was examined using a cell type (MDCK) that forms a confluent monolayer of polarized cells resulting in distinct apical (AP) and basolateral (BL) membrane domains separated by tight junctions. Because CPZ is membrane interactive, transmonolayer flux was analyzed as two kinetic events: cell uptake from the AP donor solution and efflux into the BL side receiver. Using the rate of cell uptake in the presence of different concentrations of BSA, an intrinsic cell partition coefficient of 3700 +/- 130 and an operational dissociation binding constant of 0.4 +/- 0.05 mM were calculated. In contrast to uptake, efflux of CPZ from either the AP or the BL side of the cell monolayer was approximately 10(4)-fold slower and was dependent upon the avidity of CPZ for the protein acceptor in the receiver solution. These results emphasized the importance of simultaneously measuring disappearance of a lipophilic molecule from the donor solution and its appearance in the receiver and demonstrated how interactions with proteins on either side of the cellular barrier influence permeability. Appearance kinetics showed that the composition of the receiving environment is critical to model a particular in vivo situation and implied that the intrinsic permeability of membrane-interactive molecules in vitro does not necessarily predict penetration beyond the initial cellular barrier in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8058634     DOI: 10.1023/a:1018916027099

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  20 in total

1.  Mechanisms of corneal drug penetration. II: Ultrastructural analysis of potential pathways for drug movement.

Authors:  G M Grass; J R Robinson
Journal:  J Pharm Sci       Date:  1988-01       Impact factor: 3.534

2.  Relation between binding to plasma protein, apparent volume of distribution, and rate constants of disposition and elimination for chlorpromazine in three species.

Authors:  S H Curry
Journal:  J Pharm Pharmacol       Date:  1972-10       Impact factor: 3.765

3.  The binding of chlorpromazine to some fractions of homogenized rat brain.

Authors:  A Rosen; S Y Tham
Journal:  J Pharm Pharmacol       Date:  1980-05       Impact factor: 3.765

4.  Fluorescence studies of membrane interactions of chlorpromazine and chlorimipramine.

Authors:  J G Elferink
Journal:  Biochem Pharmacol       Date:  1977-03-15       Impact factor: 5.858

Review 5.  Transport of protein-bound hormones into tissues in vivo.

Authors:  W M Pardridge
Journal:  Endocr Rev       Date:  1981       Impact factor: 19.871

6.  The asymmetric distribution of chlorpromazine and its quaternary analogue over the erythrocyte membrane.

Authors:  J G Elfernik
Journal:  Biochem Pharmacol       Date:  1977-12-15       Impact factor: 5.858

7.  Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes.

Authors:  R P Mason; S F Campbell; S D Wang; L G Herbette
Journal:  Mol Pharmacol       Date:  1989-10       Impact factor: 4.436

8.  Biological membranes as bilayer couples. A molecular mechanism of drug-erythrocyte interactions.

Authors:  M P Sheetz; S J Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1974-11       Impact factor: 11.205

9.  Characterization of a common binding site for basic drugs on human alpha 1-acid glycoprotein (orosomucoid).

Authors:  W E Müller; A E Stillbauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

10.  Partition of chlorpromazine into lipid bilayer membranes: the effect of membrane structure and composition.

Authors:  M Luxnat; H J Galla
Journal:  Biochim Biophys Acta       Date:  1986-04-14
View more
  6 in total

1.  Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model.

Authors:  S M Chung; E J Park; S M Swanson; T C Wu; W L Chiou
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

2.  Transepithelial transport of bepridil in the human intestinal cell line, Caco-2, using a "dynamic model".

Authors:  F Mathieu; M J Galmier; A Nicolay; J F Pognat; C Lartigue
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Apr-Jun       Impact factor: 2.441

3.  The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.

Authors:  B J Aungst; N H Nguyen; J P Bulgarelli; K Oates-Lenz
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

4.  Optimisation of the caco-2 permeability assay using experimental design methodology.

Authors:  Mark Lakeram; David J Lockley; Ruth Pendlington; Ben Forbes
Journal:  Pharm Res       Date:  2008-02-22       Impact factor: 4.200

5.  Transport of a novel anti-cancer agent, fenretinide across Caco-2 monolayers.

Authors:  Amit Kokate; Xiaoling Li; Bhaskara Jasti
Journal:  Invest New Drugs       Date:  2006-12-05       Impact factor: 3.651

6.  Using Human Plasma as an Assay Medium in Caco-2 Studies Improves Mass Balance for Lipophilic Compounds.

Authors:  Kasiram Katneni; Thao Pham; Jessica Saunders; Gong Chen; Rahul Patil; Karen L White; Nada Abla; Francis C K Chiu; David M Shackleford; Susan A Charman
Journal:  Pharm Res       Date:  2018-09-17       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.